Review

Role of microRNAs in inflammation-associated liver cancer

Lin Huan, Lin-Hui Liang, Xiang-Huo He
Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China

ABSTRACT
Liver cancer, primarily hepatocellular carcinoma (HCC), is a major cause of cancer-related death worldwide. HCC is a suitable model of inflammation-induced cancer because more than 90% of HCC cases are caused by liver damage and chronic inflammation. Several inflammatory response pathways, such as NF-κB and JAK/STAT3 signaling pathways, play roles in the crosstalk between inflammation and HCC. MicroRNAs (miRNAs) are evolutionarily conserved, short endogenous, non-coding single-stranded RNAs that are involved in various biological and pathological processes by regulating gene expression and protein translation. Evidence showed that miRNAs play a pivotal role in hepatitis virus infection and serve as promoters or inhibitors of inflammatory response. Aberrant miRNA was observed during liver inflammation and HCC. Many dysregulated miRNAs modulate the initiation and progression of inflammation-induced HCC. This review summarizes the role and functions of miRNAs in inflammation-associated HCC, as well as the designed therapeutics targeting miRNAs to treat liver inflammation and HCC.

KEYWORDS
MicroRNA; inflammation; liver cancer

Inflammation and liver cancer

The implication of inflammation in the development of cancers is well recognized. In the 19th century, Virchow observed leukocytes in tissues that contained inflammatory infiltrates, which later on was confirmed in several clinical cases. However, these insights were not further examined until data collected from epidemiological studies and experimental models showed a link between chronic inflammation and various types of cancers. Chronic inflammation occurs with continuous inflammatory signaling caused by viral, bacterial, and parasitic infections or chemical irritants; exposure to chemical irritants results in recruitment of inflammatory cells, increased production of reactive oxygen species (ROS), and reduced DNA repair. Most cancer tissues show specific types of inflammatory response; this subset accounts for approximately 20% of human cancers worldwide and is considered an essential component of tumorigenesis, including tumor initiation, progression, growth, and metastasis.

Liver cancer is one of the most difficult cancers to treat and is the second leading cause of cancer death worldwide, especially in China, where it accounts for half of total cancer incidence and death. Liver cancer is strongly correlated with viral hepatitis infection; more than 90% of liver cancers are associated with chronic hepatitis or liver cirrhosis. Inflammation plays an essential role in responding to harmful stimuli and insults. However, cell death-regeneration cycles are driven by persistent inflammation that occurs when inflammation-associated signaling cannot be inhibited and subsequently results in chronic injury.

Many factors provoke an inflammatory response in the liver and are well known risk factors for liver cancer. Liver cancer occurs during the progression of many chronic liver diseases associated with inflammation, such as hepatitis and steatohepatitis. Hepatitis B virus (HBV) and hepatitis C virus (HCV) are found in approximately 80%–90% of hepatocellular carcinoma (HCC) patients. HBV is an enveloped DNA virus with double-stranded circular DNA. HBV integrates into the host genome, which results in genomic instability. Chronic HBV infection is the dominant risk factor for liver cancers in Asia and Sub-Saharan Africa, particularly in China. HCV is a single-stranded RNA virus that interacts with numerous proteins in hepatocytes and promotes the progression of hepatocarcinogenesis. Chronic HCV infection is the dominant risk factor for liver cancers in Japan, United States,
and Europe. Cirrhosis contributes to hepatocarcinogenesis and is observed in most HCC patients with HBV or HCV infection\textsuperscript{14}.

In addition to these viral infections, acetaldehyde and other metabolites generated by alcohol metabolism increase the amount of ROS and reduce DNA repair, which leads to HCC\textsuperscript{15}. Epidemiological analysis revealed that alcohol consumption is positively associated with HCC incidence; diabetes is another risk factor for HCC because epidemiologic studies reported that patients with type 2 diabetes have nearly 2.5-fold increased risk for HCC\textsuperscript{16,17}. Recently, obesity was defined as a risk factor with an important role in HCC development\textsuperscript{18}. Inflammation induced by viral or non-viral infection promotes the initiation and progression of HCC; HCC develops in the background of chronic hepatitis\textsuperscript{19}.

Several signaling pathways link inflammation and cancer. Constitutive activation of these inflammatory signaling pathways, such as NF-κB and JAK/STAT signaling pathways, occurs during the process of inflammation and is observed in various cancers. The first link between NF-κB and cancer was revealed in a study showing that cancer cells were more sensitive to apoptosis-inducing stimuli after the NF-κB signaling pathway was blocked\textsuperscript{20}. Over the past decades, the diverse roles of NF-κB signaling have been discovered in various types of carcinomas, including head and neck squamous cell carcinoma, leukemia, and cancers of breast, liver, prostate, colon, and lung\textsuperscript{21}. Constitutive NF-κB activation was observed in various cancers, where NF-κB induces the expression of many pro-survival and anti-apoptotic factors, such as c-IAP, XIAP, and members of the Bcl-2 family of proteins\textsuperscript{22,23}. Analogously, the activation of NF-κB might downregulate the expression of tumor suppressors, such as phosphatase and tensin homolog (PTEN); the downregulated expression increases Akt signaling and suppresses the apoptosis of cancer cells\textsuperscript{24}. In addition to its pro-survival function, NF-κB promotes cell cycle progression by inducing cyclin D1 and c-myc expression\textsuperscript{25,26}. NF-κB signaling can also induce molecules such as vascular endothelial growth factor (VEGF) and matrix metalloproteinases, and NF-κB can promote angiogenesis and invasion by driving the expression of these proteins in many cancers\textsuperscript{27}. In 2004, a group from Israel confirmed that NF-κB is an effective therapeutic target to treat HCC\textsuperscript{28}. HCC development in a mouse model was prevented through NF-κB inhibition by a modified form of IκB called super-repressor IκB.

Another well-known signaling pathway that links inflammation and cancer is the Janus kinase (JAK)/signal transducer and activator of transcription (STAT). This signaling pathway is also constitutively activated in most cancers. STAT3, one of the most famous STAT family members, was identified as a transcription factor that binds to the IL-6-responsive element in hepatocytes\textsuperscript{29}. This binding suggests that STAT3 is a key regulator of inflammation. However, inflammatory cytokines are not the only factors that activate STAT3 signaling. Numerous studies reported that STAT3 can also be activated by oncogenic proteins including Ras or Src\textsuperscript{30,31}. Carcinogens, such as polychlorinated biphenyls, promotes liver cancer and regulates the activity of STAT3 in HCC and normal liver cells\textsuperscript{32}. Therefore, STAT3 is a key role in inflammation regulation and cancer development. Likewise, the constitutive activation of STAT3 leads to the expression of Bcl-2 family proteins essential for survival, such as survivin and cIAP2; moreover, the apoptosis of cancer cells occurs when STAT3 is downregulated in tumors\textsuperscript{33-36}. STAT3 promotes the proliferation of cancer cells by inducing cyclin D1 and c-myc expression\textsuperscript{37,38}. In addition to molecules associated with proliferation and apoptotic inhibition, STAT3 regulates the expression of the metalloproteinase family and VEGF, consequently promoting angiogenesis and metastasis\textsuperscript{39}. STAT3 is also activated in hepatocytes following interleukin stimulation. STAT3 is a key regulator of inflammation and cancer and thus might be an effective therapeutic target in inflammation-induced cancer. In 2006, Li et al.\textsuperscript{40} inhibited STAT3 expression with antisense oligonucleotides in HCC cells and found that STAT3 greatly reduced cell proliferation and migratory potential as well as induced apoptosis.

**MiRNAs are a novel class of molecules linking inflammation and HCC**

MiRNAs constitute a class of short endogenous non-coding RNAs that are highly conserved throughout evolution. The biogenesis of miRNAs requires multiple steps. The majority of miRNAs are transcribed in the nucleus by RNA polymerase II as a primary miRNA (pri-miRNA); the typical pri-miRNA contains stem-loop structures. Furthermore, these stem-loop structures are cleaved into precursor miRNAs (pre-miRNAs) by Drosha, an RNA-specific ribonuclease enzyme complex. Dicer functions in the biogenesis of miRNAs as pre-miRNAs are transported from the nucleus into the cytoplasm by Exportin 5\textsuperscript{41}. Dicer is an endonuclease that specifically recognizes double-stranded RNA complexes and transforms the pre-miRNA into a 20–22
protein (HBx) encoded by the HBV genome is a multifunctional transactivator that plays crucial roles in HBV-associated hepatocarcinogenesis. HBx lacks a DNA binding domain and acts as a trans-coactivator through interaction with other cellular transcription factors, by which HBx might regulate let-7 family members. In addition to HBx induction, HBV preS2 RNA can sequester let-7g, which in turn reduces intrinsic let-7g functions in HCC.[11] Wang et al.[49] concluded that HBx-mediated down-regulation of let-7 might be responsible for reduced let-7 expression in HBV-associated HCC. MiRNAs from the let-7 family act as tumor suppressors in HCC by inhibiting proliferation and invasion, as well as inducing apoptosis by targeting many oncogenes including high mobility group proteins, Bel-xL, STAT3, and c-myc.[51,112,113] Further clinical research suggested that let-7 expression level is associated with poor differentiation.[114] MiR-122

MiR-122 is the most abundant miRNA expressed in the liver, which accounts for 70% of the total miRNAs in an adult liver.[115] The expression of miR-122 is increased in the liver during embryonic development, and the first identified target of this miRNA is cationic amino acid transporter 1.[116] In recent years, increasing evidence suggested that miR-122 plays an important role in initiation and progression of HCC. Li et al.[117] found that miR-122 expression is low in patients with chronic hepatitis B and HCC tumors and has negative correlation with fibrotic stage, age, and liver transaminase levels. The downregulation of miR-122 in patients with chronic hepatitis B and HCC tissues is affected by HBV infection. HBx overexpression reduces the expression of miR-122[118], PPARγ was identified as a transcription factor regulating miR-122 expression; the underlying cause of HBx-induced miR-122 downregulation might be the direct interaction between HBx and PPARγ, which blocks PPARγ nuclear translocation.[119] In 2013, Li et al.[120] further reported that all four HBV mRNAs contain a binding site for miR-122 and act as a miRNA sponge sequestering miR-122 in HBV-infected cells. In addition, miR-122 knockout mice will possibly develop hepatitis, fibrosis, and HCC. The reduced miR-122 expression in HCC tissues is characterized by a poor prognosis and consistent with a suppressed hepatic phenotype and an increased metastatic potential.[121] Moreover, miR-122 expression can be suppressed by two inflammatory cytokines, IL-6 and TNF-α, which downregulate the miR-122 transcription factors C/EBPα and HNF3β and induce c-myc-mediated C/EBPα inhibition in chronic hepatic inflammation.[117] MiR-122 downregulation results in the upregulation of target genes that promote hepatocarcinogenesis, including pituitary tumor trans-
forming gene binding factor (PBF), cyclin G1, PKM2, ADAM10, ADAM17, SRF, and PKR activator\textsuperscript{122-124}. MiR-101 is another miRNA that is downregulated by HBV infection\textsuperscript{125}. HBV downregulates miR-101 expression by inhibiting its promoter activity. MiR-101 downregulation was reported in various cancers, including HCC, suggesting that miR-101 functions as a tumor suppressor\textsuperscript{52,126}. Reduced miR-101 expression in HCC tissues is associated with

### Table 1 MiRNAs associated with hepatitis virus infection and HCC

| Name     | Regulated by | Expression | Target(s) in HCC                  | Reference |
|----------|--------------|------------|-----------------------------------|-----------|
| Let-7    | HBV          | Down       | RAS, HMGA2, MYC, STAT3             | 48-51     |
| MiR-101  | HBV          | Down       | MCL1                              | 52,53     |
| MiR-132  | HBV          | Down       | PIK3R3                            | 54,55     |
| MiR-136  | HBV          | Down       | AEG1                              | 56        |
| MiR-145  | HBV          | Down       | ROCK1, ADAM17, HDAC2              | 57-61     |
| MiR-148  | HBV          | Down       | HP1P                              | 62        |
| MiR-15b  | HBV          | Down       | FUT2, Rab1A                       | 63,64     |
| MiR-205  | HBV          | Down       | ACSL1                             | 65,66     |
| MiR-216  | HBV          | Down       | IGF2BP2                           | 67        |
| MiR-223  | HBV          | Down       | MYC                               | 68        |
| MiR-29c  | HBV          | Down       | TNFAIP3                           | 69        |
| MiR-338-3p| HBV         | Down       | TAZ, CCND1, HIF1A, FOXP4           | 70-73     |
| MiR-375  | HBV          | Down       | AEG1                              | 56        |
| MiR-429  | HBV          | Down       | NOTCH1, Rab18                      | 74,75     |
| MiR-103/107 | HBV    | Up         | Maspin, AKAP12                     | 76,77     |
| MiR-106b | HBV          | Up         | APC1                              | 78,79     |
| MiR-125a | HBV          | Up         | MMP11, VEGF                       | 80,81     |
| MiR-146a | HBV          | Up         | CFH, VEGF                         | 82,83     |
| MiR-181a | HBV          | Up         | Fas, Met, E2FS                     | 84-86     |
| MiR-18a  | HBV          | Up         | CTGF                              | 87        |
| MiR-19a  | HBV          | Up         | PTEN                              | 68        |
| MiR-21   | HBV          | Up         | Maspin                            | 76        |
| MiR-29a  | HBV          | Up         | PTEN                              | 88        |
| MiR-331-3p| HBV        | Up         | VHL, ING5                         | 89,90     |
| MiR-33a  | HBV          | Up         | PBX3, TWIST1                       | 91,92     |
| MiR-602  | HBV          | Up         | RASSF1A                           | 93        |
| MiR-122  | HBV, HCV     | Down       | CAT1, PEG10                       | 94,95     |
| MiR-152  | HBV, HCV     | Down       | DNMT1, Wnt1                       | 96,97     |
| MiR-221  | HBV, HCV     | Up         | ERα                               | 98,99     |
| MiR-181c | HCV          | Down       | HOXA1                             | 100       |
| MiR-203a | HCV          | Down       | ADAM9                             | 101,102   |
| MiR-30c  | HCV          | Down       | Snail                             | 101,103   |
| MiR-155  | HCV          | Up         | APC                               | 104       |
| MiR-196a | HCV          | Up         | FOXO1                             | 105       |

Huan et al. MiRNAs linking inflammation and HCC
advanced tumor progression and poor survival in HCC patients; the serum miR-101 level might be a potential HCC biomarker. Overexpression of miR-101 sensitizes the HCC cells to apoptosis induced by serum deprivation and chemotherapeutic drugs. Mcl-1, a member of the Bcl-2 family, is a target of miR-101 and sensitizes cancer cells to apoptosis. MiR-101 enhances cisplatin-induced apoptosis by targeting STMN1, RAB5A, and mTOR, as well as suppresses epithelial-mesenchymal transition (EMT) in hepatocytes via the regulation of ZEB1 expression, which results in E-cadherin down-regulation.

**MiR-155**

In 2010, the first link between miR-155 and hepatitis viruses was based on the observation that miR-155 precursor (termed BIC) is responsible for HCV infection. After patients with hepatitis C were treated with interferon alpha and ribavirin, the lowest BIC expression was detected in patients who lacked HCV RNA in both serum and peripheral blood mononuclear cells. Previously, miR-155 was identified as an onco-miR in various cancers, including lung, breast, stomach, and prostate cancers. A mouse model revealed that miR-155 induced by inflammation could promote autoimmune inflammation by enhancing inflammatory T cell development. MiR-155 up-regulation occurs before HCC carcinogenesis. A positive correlation was observed between miR-155 expression and IP-10 levels in the plasma, which is widely considered a marker of liver inflammation degree. Upon NF-κB activation by HCV-RNA infection, miR-155 expression is induced. The upregulation of miR-155 in cases of hepatitis and HCC promotes hepatocyte proliferation and HCC tumor growth by activating the Wnt/β-catenin signaling pathway. In addition to HCC pathogenesis during chronic viral infections such as HCV, the upregulation of miR-155 was also observed in the pathogenesis of non-alcoholic steatohepatitis (NASH)-associated HCC. However, similar to HCV-induced miR-155, the activation of NF-κB signaling pathway plays a key role in miR-155 expression in HCC and other hepatocyte-derived cells. In a mouse model of NASH, miR-155 downregulated the tumor suppressor target C/EBPβ, thus promoting liver pathogenesis.

**MiR-221**

MiR-221 is another onco-miR that is upregulated in cancers such as breast, prostate, glioma, and liver cancers. Moreover, the expression of miR-221 in later stages of HCC is higher than that in early stages. Therefore, miR-221 is a poor prognosis risk factor because it was increased in mouse models of liver fibrosis and upregulated in the human liver in a fibrosis progression-dependent manner. Overexpression of miR-221 in isolated and purified primary hepatocytes increases cell proliferation. HBx promotes the proliferation of HCC cells and upregulates the expression of miR-221 during both HBV infection and HCC. HCV infection can also induce the upregulation of miR-221. Several tumor-related genes were reported to be the targets of miR-221; among these genes, p27Kip1 is well-recognized. The expression of miR-221/p27Kip1 axis was confirmed in glioblastomas, breast, lung, and liver cancers. Other than p27Kip1, many miR-221 targets were reported, such as HDAC6, PTEN, and tissue inhibitor of metalloproteinase-3 (TIMP3). In mouse models of HCC, tumor-bearing mice that were treated with chol-anti-miR-221 have a survival advantage compared with mice in the control group. MiR-221 is a potential target for HCC treatment and functions by inhibiting the progression of HCC and promoting survival. MiR-221 transgenic animal models exhibited a strong predisposition toward the development of HCC.

**MiRNAs as regulators of inflammatory signaling in HCC**

Chronic inflammation can facilitate the development and
progression of HCC by the constitutive activation of inflammation signaling pathways. Aberrant activation of these pathways promotes inflammation-associated hepatocarcinogenesis. Inhibition of these signaling pathways would be a novel therapeutic strategy to suppress this inflammation-associated process. Many miRNAs were reported to regulate the inflammatory signaling mediated by NF-κB and JAK/STAT3, among others, in HCC (Table 2). Our group screened several miRNAs that might suppress NF-κB activation. Among these miRNAs, miR-195, miR-194, and miR-127 suppressed NF-κB activation by directly or indirectly targeting NF-κB signaling; these miRNAs also function as tumor suppressors in HCC. MiR-219 is reduced in HCC where it functions as a tumor suppressor; this miRNA might suppress JAK/STAT3 signaling via direct targeting of structural maintenance of chromosome 4 protein (SMC4). MiR-637 is a tumor suppressor that inhibits cell growth and induces apoptosis by suppressing STAT3 activation in HCC. Some typical miRNAs that behave as regulators in inflammatory signaling are summarized below.

**MiR-26a**

MiR-26a was suggested to play an important role in cirrhosis and inflammation-induced HCC. Reduced miR-26a

| Name      | Targets in HCC | Promote/inhibit | Downstream signaling | Reference |
|-----------|----------------|-----------------|----------------------|-----------|
| MiR-127-5p| BLVRB          | Inhibit         | NF-κB                | 160       |
| MiR-129-5p| VCP            | Inhibit         | NF-κB                | 161       |
| MiR-194   | TRIM23, C21orf91 | Inhibit       | NF-κB                | 162       |
| MiR-195   | TAB 3, IKKα    | Inhibit         | NF-κB                | 163       |
| MiR-26b   | TAK1, TAB 3    | Inhibit         | NF-κB                | 164       |
| MiR-302b  | AKT2           | Inhibit         | NF-κB                | 165       |
| MiR-342-3p| IKKγ, TAB 2, TAB 3 | Inhibit    | NF-κB                | 166       |
| MiR-370   | Lin28A         | Inhibit         | NF-κB                | 167       |
| MiR-491   | SMAD3          | Inhibit         | NF-κB                | 168       |
| MiR-520e  | NIK            | Inhibit         | NF-κB                | 169       |
| MiR-622   | MAP4K4         | Inhibit         | NF-κB                | 170       |
| MiR-1180  | OTUD7B, TNIP2  | Promote         | NF-κB                | 171       |
| MiR-301a  | GAX            | Promote         | NF-κB                | 172       |
| MiR-362-5p| CYLD           | Promote         | NF-κB                | 173       |
| MiR-4262  | PDCD4          | Promote         | NF-κB                | 174       |
| MiR-657   | TLE            | Promote         | NF-κB                | 175       |
| MiR-451   | IKKβ, IL6R     | Inhibit         | NF-κB, STAT3         | 176-177   |
| Let-7     | STAT3          | Inhibit         | STAT3                | 48        |
| MiR-122   | c-Met          | Inhibit         | STAT3                | 178       |
| MiR-124   | STAT3          | Inhibit         | STAT3                | 179       |
| MiR-125b  | IL6R           | Inhibit         | STAT3                | 180       |
| MiR-130b  | IRF            | Inhibit         | STAT3                | 181       |
| MiR-197   | STAT3          | Inhibit         | STAT3                | 182       |
| MiR-219   | SMC4           | Inhibit         | STAT3                | 183       |
| MiR-26a   | IL6            | Inhibit         | STAT3                | 184       |
| MiR-363   | S1PR1          | Inhibit         | STAT3                | 185       |
| MiR-637   | LIF            | Inhibit         | STAT3                | 186       |
| MiR-155   | SOCS1          | Promote         | STAT3                | 187       |
expression was detected in HCC tissues; the decreased expression in HCC tissues might be an independent predictor of poor survival\textsuperscript{188}. Clinical analysis revealed that the expression of miR-26a is negatively correlated with IL-6 mRNA and IL-6 protein level. As IL-6 is a direct target of miR-26a, the mRNA and protein levels of this cytokine are significantly reduced by miR-26a overexpression in HCC cells. MiR-26a functions as a tumor suppressor that inhibits tumor growth and metastasis, partly through the IL-STAT3 signaling pathway\textsuperscript{184}. Furthermore, miR-26a regulates the recruitment of macrophages\textsuperscript{190}. M-CSF expression was also reported as a predictor of frequent metastasis and poor survival; miR-26a affects macrophage polarization and inhibits macrophage recruitment by down-regulating M-CSF expression\textsuperscript{191}. In addition, HCC cells transfected with miR-126b exhibit significantly reduced NF-κB reporter activity in response to TNFα. Two well-known upstream regulators of NF-κB signaling pathway, TAK1 and TAB 3, were identified as direct targets of miR-26b. MiR-26b prevents doxorubicin-induced NF-κB activation and promotes apoptosis in HCC cells\textsuperscript{164}.

**MiR-451**

In one study, miR-451 was often downregulated in primary HCC tissues; reduced miR-451 expression was significantly associated with advanced TNM stage, lymph node metastasis, vascular invasion, and poor survival, indicating that miR-451 might act as a tumor suppressor in HCC\textsuperscript{192}. MiR-451 might inhibit HCC tumorigenesis and metastasis by down-regulating cyclin D1 and c-myc at both mRNA and protein levels. Further study indicated that miR-451 overexpression affected the NF-κB nuclear translocation and significantly decreased NF-κB activity by directly targeting IκKβ. As expected, the inhibition of miR-451 significantly increased NF-κB activity in HCC cells\textsuperscript{176}. Moreover, a recent study revealed that reduced expression of the IL-6 receptor was observed in cells that overexpressed miR-451, and that IL-6 receptor was a direct target of miR-451. MiR-451 reduced VEGF production in HCC cells by targeting the IL-6/STAT3 signaling pathway\textsuperscript{177}.

**MiR-124**

MiR-124 is a well-known tumor suppressor that is frequently downregulated in various cancers. Numerous studies revealed that miR-124 inhibits inflammatory signaling by targeting STAT3 in different cancer types including glioblastoma, gastric cancer, endometrial cancer, colon cancer, and HCC\textsuperscript{179,193-196}. Recently, NF-κB p65 was reported to be a direct miR-124 target in B-cell lymphomas. The downregulation of miR-124 in B-cell lymphomas enhances the NF-κB signaling pathway and upregulates genes, such as myc and Bcl-2, associated with proliferation, anti-apoptosis, metastasis, and pro-survival\textsuperscript{197}. STAT3 was identified as a direct miR-124 target in HCC; one study found that miR-124 inhibited cell proliferation and induced apoptosis in HCC cells by targeting STAT3\textsuperscript{179}. Moreover, an HNF4α-NF-κB feedback circuit that includes miR-124 was identified in HCC. Reduced HNF4α could be a biomarker for poor prognosis, as HNF4α suppresses HCC metastasis by inhibiting NF-κB activation. MiR-124 also plays an important role in RelA suppression by HNF4α. MiR-124 was identified as an HNF4α target that binds to the 3'UTR of RelA. MiR-124 significantly downregulates RelA expression, represses NF-κB activation, and inhibits HCC tumorigenesis\textsuperscript{198}.

**MiR-125b**

MiR-125b is a well-recognized miRNA that participates in innate immune response\textsuperscript{199}. Our group was the first to reveal the role of miR-125b in HCC. We discovered that miR-125b was significantly downregulated in HCC, could be used as a biomarker for prolonged HCC patient survival, and functions as a tumor suppressor\textsuperscript{41}. MiR-125b inhibits the proliferation of HCC cells by inducing cell cycle arrest during G1/S transition via its target gene, Lin28B\textsuperscript{200}. Zhao et al.\textsuperscript{201} found that miR-125b induced HCC apoptosis by suppressing Bcl-2. IL-6R was identified as a direct target of miR-125b. IL-6R was characterized as the subunit that binds to IL-6; the binding of IL-6 to IL-6R activates the JAK/STAT3 signaling pathway. MiR-125b can block the IL-6-induced phosphorylation and nuclear translocation of STAT3 in HCC cells, which in turn promotes HCC apoptosis\textsuperscript{180,202}. In addition, miR-125b serves as a tumor suppressor that inhibits migration and invasion of HCC cells by targeting the transcriptional co-activator with PDZ-binding motif (TAZ). MiR-125b can also suppress EMT by downregulating SMAD2 and SMAD4\textsuperscript{203,204}. EZH2 was also associated with miR-125b downregulation\textsuperscript{205}.

**MiR-370**

The role of miR-370 in carcinogenesis is controversial. Several studies revealed that miR-370 acts as tumor promoter in gastric cancer, prostate cancer, and AML; whereas other studies reported miR-370 as a tumor suppressor in leukemia and oral squamous carcinoma\textsuperscript{206-210}. Xu et al.\textsuperscript{167} observed that the down-regulation of miR-370 was associated with HCC development in rats and correlated with poor survival in HCC patients, indicating that miR-370 serves as a tumor...
suppressor in HCC. The restoration of miR-370 inhibits proliferation, migration, and invasion of HCC cells and suppresses tumorigenesis of HCC by directly targeting Lin28A. Lin28A is a post-transcriptional modulator of mRNAs that can directly bind to p65 mRNA. MiR-370 represses NF-κB activation and inhibits the migration and invasion of HCC cells through downregulation of Lin28A. Sun et al. confirmed the tumor suppressor role of miR-370 in HCC cells, showing that miR-370 inhibited HCC cell proliferation and colony formation ability by activating the PI3K/Akt signaling pathway.

In addition to miRNAs that inhibit inflammatory signaling, some miRNAs, such as miR-155, miR-362, miR-301a, and miR-1180, promote the inflammatory response by repressing negative regulators of inflammatory signaling. MiR-1180 is frequently upregulated in HCC tissues and HCC-derived cell lines. The NF-κB signaling pathway is activated by miR-1180 overexpression, which occurs through the downregulation of miR-1180 direct targets, OTUD7B and TNIP2. Another study confirmed the expression of TNIP2, a direct target of miR-1180, in HCC cells. The ectopic expression of miR-1180 promoted the proliferation of HCC cells and inhibited apoptosis because NF-κB induces the expression of genes that participate in pro-survival and anti-apoptotic processes. Ni et al. demonstrated that miR-362-5p, which is frequently upregulated in HCC, promoted NF-κB signaling by downregulating CYLD; CYLD is a protein that binds to NF-κB essential modulator and functions as a negative regulator of NF-κB signaling.

**MiRNAs as mediators of inflammatory signaling in HCC**

Inflammatory signaling pathway activation was associated with hepatocarcinogenesis. These inflammatory pathways and related transcription factors can affect the development of HCC by regulating miRNA expression. Several studies confirmed that inflammatory signaling facilitates the development of HCC through the downregulation or upregulation of miRNAs in cells (Table 3).

### MiR-21

Ning et al. observed feedback regulation of HNF4α and NF-κB in HCC. Their study revealed that HNF4α dramatically suppresses the NF-κB signaling pathway and that RelA overexpression or knockdown decreases or increases the expression of HNF4α, respectively. During chronic hepatic inflammation, NF-κB induced the expression of miR-21, which represses HNF4α expression and contributes to hepatocyte de-differentiation and hepatocarcinogenesis. In addition to direct induction of miR-21 expression by NF-κB, miR-21 transcriptional activity is enhanced by high-mobility group box-1 protein (HMGB1), an important participant in inflammation. HMGB1 is a conserved nuclear protein that functions as a chromatin binding factor and allows transcription factors to access specific DNA binding sites. HMGB1 enhances p65/p50 or p50/p50 binding to specific DNA sites rather than the binding of p65/p65, c-Rel/c-Rel, p65/c-Rel, and p50/c-Rel. Given its role in the inflammatory cascade, HMGB1 is upregulated in HCC and induces miR-21 expression in HCC cells. The HMGB1/miR-21 signaling axis inhibits the downstream targets RECK and TIMP3 as well as promotes cell proliferation, invasion, and migration.

### MiR-143

MiR-143 is upregulated in HCC tissues, indicating that miR-143 serves as a tumor promoter. MiR-143 expression was increased by HBx-mediated NF-κB activation, although metastasis will be suppressed by miR-143 inhibition. NF-κB activates transcription by specifically binding to the putative miR-143 promoter, as the NF-κB binding site

| Name | Regulated by | Expression | Target(s) in HCC | Reference |
|------|--------------|------------|-----------------|-----------|
| MiR-197 | IL6 | Down | STAT3 | 182 |
| MiR-143 | NF-κB | Up | FNDC3B | 214 |
| MiR-155 | NF-κB | Up | C/EBPβ | 132 |
| MiR-221 | NF-κB | Up | HDAC6 | 99,157 |
| MiR-224 | NF-κB | Up | ARHGAP9, ARHGAP21 | 215 |
| MiR-21 | NF-κB, STAT3 | Up | PTEN, RECK, PSCD4 | 216,217 |
| MiR-146a | STAT3 | Up | VEGF | 107 |
| MiR-23a | STAT3 | Up | PGC-1α, G6PC | 218 |
identifies 5.06 kb upstream of miR-143. MiR-143 promotes cell invasion and tumor metastasis by suppressing the direct target gene FNDC3B. Moreover, miR-143 inhibition results in apoptosis of HCC cells and suppression of HCC tumorigenesis\textsuperscript{222}. In addition, miR-143 was upregulated in serum samples from patients with chronic hepatitis and HCC and therefore might be a useful biomarker for both diseases\textsuperscript{223}.

\textbf{MiR-221}

In addition to the upregulation of miR-221 by HBV, miR-221 can also be induced by HCV infection in an NF-κB-dependent manner\textsuperscript{99}. MiR-221 and NF-κB expression are upregulated after HCV infection. However, the increased expression of miR-221 was blocked after treatment with PDTC, an NF-κB inhibitor. This finding suggests that the HCV-induced upregulation of miR-221 requires NF-κB activation and that NF-κB signaling pathway plays an important role in inflammation-associated cancer.

\textbf{MiR-224}

The expression of miR-224 was upregulated in both cirrhotic livers and HCC samples, suggesting the use of miR-224 as a biomarker of liver inflammation and HCC. The upregulation of miR-224 begins in the pre-cancerous stage and continues during HCC development\textsuperscript{224}. In one study, patients with lower miR-224 expression exhibited a favorable trend of survival. In addition, miR-224 levels were significantly higher in patients with advanced HCC stages than in patients with early stages. MiR-224 could be induced by a set of pro-inflammatory factors, such as TNFα, LPS, and LTA, suggesting that NF-κB signaling regulates miR-224. NF-κB binds to the regulatory region of miR-224 and upregulates miR-224 expression\textsuperscript{215}. Inflammation-mediated activation of miR-224 promotes HCC cell migration and invasion by targeting Rho GTPase-activating proteins. As an onco-miR, the overexpression of miR-224 also facilitates the migration and invasion of HCC cells by targeting HOXD10 and promotes proliferation by targeting p21\textsuperscript{225,226}.

\textbf{MiR-197}

MiR-197 is well-studied during the progression of various cancers in which it plays a role in apoptosis, proliferation, angiogenesis, metastasis, and drug resistance. A negative correlation between miR-197 expression and IL-6 and STAT3 protein levels was observed in HCC tissues, indicating that miR-197 is involved in the STAT3 signaling pathway\textsuperscript{182}. IL-6 is a well-known pro-inflammatory factor that is upregulated during an inflammatory state\textsuperscript{227}. The expression of mature miR-197 was reduced by IL-6 stimulation, whereas the expression of pri-miR-197 remained unchanged by IL-6 stimulation in HCC cells. Further investigation revealed that Drosha binding to pri-miR-197 decreased after IL-6 stimulation, indicating that IL-6 downregulated miR-197 in a post-transcriptional manner by inhibiting Drosha binding to pri-miR-197. Moreover, STAT3 was identified as a direct target of miR-197. As a tumor suppressor, miR-197 inhibits proliferation and invasiveness of HCC cells as well as suppresses the tumorigenesis of HCC xenografts\textsuperscript{182}.

\textbf{MiR-23a}

The first evidence of the role of miR-23a in HCC development was revealed in 2008. MiR-23a induced by TGFβ is remarkably increased in HCC tissues and functions as an anti-apoptotic and pro-proliferative factor in HCC cells\textsuperscript{228}. Later on, Wang et al.\textsuperscript{218} found that miR-23 can be induced by IL-6 and STAT3 signaling, as a potential STAT3 binding site was identified in the miR-23a promoter region. STAT3-activated miR-23a downregulates the target genes G6PC and PCG-α and suppresses gluconeogenesis; this reduction in gluconeogenesis facilitates HCC tumorigenesis.

\textbf{MiRNAs as therapeutic targets in inflammation-related HCC}

MiRNAs have a well-recognized role in liver inflammation and hepatocarcinogenesis; many miRNAs are dysregulated during chronic liver inflammation and HCC progression. miRNAs were regarded as novel targets for HCC therapy; the first study using miRNA-based therapy was conducted in 2005. In that study, miR-122 expression was silenced by antagonirs, which act as efficient and specific silencers of endogenous miRNAs. One particular antagonir was injected into mice and dramatically reduced endogenous miR-122 levels\textsuperscript{229}. MiR-122 is a liver-enriched miRNA that functions as a tumor suppressor. A clinical trial of treating HCV infection by miR-122 inhibition was performed because miR-122 targets HCV genomic RNA and promotes HCV viral translation. Jong-Kook Park and colleagues treated tumor-bearing mice with chol-anti-miR-221 or a cholesterol-labeled control oligo. Consistent with the \textit{in vitro} results, improved survival was observed in the group of mice treated with chol-anti-miR-221\textsuperscript{158}.

In addition, miR-21 is a tumor promoter and functions as a prognostic factor, as previously described. MiR-21 promotes the proliferation, metastasis, and tumorigenesis of HCC and was validated as an onco-miR involved in drug resistance. MiR-21 suppression by lenti-miR-21-i combined
with 5-fluorouracil and pirarubicin treatment leads to significant suppression of HCC cell proliferation; 5-fluorouracil and pirarubicin downregulated the miR-21 expression through AP-1 signaling\textsuperscript{230}.

Oncolytic viruses were proposed as a novel therapeutic strategy for cancer treatment. Ad5-based oncolytic viruses were proven effective and safe in clinical trials\textsuperscript{231}. MiR-199 is significantly reduced in HCC tissues compared with normal tissues. MiR-199 was cloned into adenoviral vectors to produce miR-199 adenovirus. Tumor-bearing nude mice were intra-tumorally injected with either miR-199 adenovirus or PBS as a control. Tumor growth was dramatically suppressed in the group of mice treated with miR-199 adenovirus. These results were confirmed in a transgenic model in which mice were predisposed to HCC development. The group of mice treated with miR-199 adenovirus exhibited a reduced tumor burden and a decreased number of tumor nodules compared with the control group. It can be expected in the future that any miRNAs acting as tumor suppressors can be applied as therapeutic oncolytic viruses in a manner similar to miR-199\textsuperscript{232}.

Another miRNA-based therapeutic strategy is the design of miRNA panels that targets a particular protein to modulate inflammatory response and HCC development. For example, repressor/activator protein (Rap) might protect telomeres. Rap1 is an integral component of the \(I\kappa B\) kinase (IKK) complex. The association between the IKK complex and Rap1 is important for NF-\(\kappa B\) activation because Rap1 serves as an adaptor to recruit IKKs and aids in phosphorylation of the NF-\(\kappa B\) p65 subunit\textsuperscript{233}. Rap1 knockdown sensitized cancer cells to chemotherapeutic drug-induced apoptosis. 5-fluorouracil is a widely used chemotherapy drug for advanced HCC patients, but many patients with HCC are highly resistant to this chemotherapy regimen. A set of 4 Rap1-miRNAs was designed to knock down Rap1, leading to a significant increase in the sensitivity of HepG2 cells to 5-fluorouracil-induced apoptosis\textsuperscript{234}.

A number of miRNAs can be induced or inhibited during hepatitis because of viral or non-viral infections. Some miRNAs are also activated or repressed when inflammatory signaling pathways, such as NF-\(\kappa B\) and JAK/STAT3 signaling, cannot be turned off. In turn, miRNAs that might function as oncogenes or tumor suppressors can promote or suppress both inflammatory cascades in hepatocarcinogenesis. This function indicates that miRNAs are novel regulators or mediators of liver inflammation and hepatocarcinogenesis (Figure 1). Tumor tissues can be highly complex and heterogeneous. The tumor microenvironment consists of many types of cells including tumor invading immune-cells, fibroblasts, vascular endothelial cells, lymphatic cells, and stromal components. Given that numerous components of tumor microenvironment are responsible for the initiation, development, and progression of human cancer\textsuperscript{235}, the dysregulated miRNAs from tumor specimens might originate from different types of cells in the tumor microenvironment.

![Figure 1](image-url)  

**Figure 1** A simplified sketch illustrates the development of liver inflammation and HCC and shows the key nodes in which aberrantly expressed miRNAs participate in inflammation-associated hepatocarcinogenesis. Many miRNAs are aberrantly expressed when liver inflammation occurs and play prominent roles in HCC development. MiRNAs might be regulated by constitutive inflammatory signaling pathways and participate in the development and progression of HCC. Additionally, miRNAs might modulate the inflammatory signaling pathways during the development and progression of HCC.
and function in human carcinogenesis by multiple ways. The next investigations should focus on the origin, location, action, and multi-function of the dysregulated miRNAs in initiation, development, and progression of HCC. Additionally, any study of cell lines might run the risk of false discovery. The results from cell lines cannot reflect the full aspects of the pathological process of HCC. The next investigations on the exact role of miRNAs in inflammation-associated HCC should be verified in patients and reliable HCC models.

The 5-year overall survival of HCC is lower than 10% worldwide because many patients are diagnosed at advanced stages. Therefore, discovering novel viable biomarkers for HCC early diagnosis is urgent. In the last decades, numerous pieces of evidence highlighted the regulatory roles of miRNAs in inflammation-associated HCC. Evidence also indicated that the dysregulated miRNAs might be useful as biomarkers for liver inflammation and HCC progression. In 2015, miRNAs were screened in a large-scale, multicenter, retrospective longitudinal study to explore effective and reliable strategies for monitoring at-risk populations that suffers from chronic inflammation as well as detect HCC at an early stage. Serum miR-29a, miR-29c, miR-133a, miR-143, miR-145, miR-192, and miR-505 might act as biomarkers in HCC because they are in significantly higher content in HCC compared with healthy controls or those with chronic inflammation. The classifier composed of these seven miRNAs could be more sensitive than α-fetoprotein in distinguishing patients with HCC from those who are cancer-free. The distinction requires large-scale, multicenter, independent investigations to confirm its feasibility. Several studies illustrated the potential of miRNAs as therapeutic targets to prevent or treat HCC. However, additional profiles and detailed mechanisms of miRNA functions are required to provide a better understanding of their role in liver inflammation and hepatocarcinogenesis. The additional data will facilitate the application of more miRNAs into prevention and therapy for inflammation-associated HCC.

Acknowledgments

This work was supported by grants from the National Key Basic Research Program (Grant No. 2013CB910504), and the National Natural Science Foundation of China (Grant No. 81125016 and 81472565).

Conflict of interest statement

No potential conflicts of interest are disclosed.

References

1. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008; 454: 436–44.
2. Bryant T. Remarks on some cases of inflammation of the breast simulating cancer. Br Med J. 1868; 2: 608–9.
3. Balkwill F, Mantovani A. Inflammation and cancer: back to vichow? Lancet. 2001; 357: 539–45.
4. Karin M. Nuclear factor-xb in cancer development and progression. Nature. 2006; 441: 431–6.
5. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420: 860–7.
6. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology. 2002; 16: 217–26, 229; discussion 230–2.
7. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140: 883–99.
8. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: Cancer J Clin. 2015; 65: 87–108.
9. Edmondson HA, Peters RL. Tumors of the liver: pathologic features. Semin Roentgenol. 1983; 18: 78–83.
10. Qiao L, Li X. Role of chronic inflammation in cancers of the gastrointestinal system and the liver: where we are now. Cancer Lett. 2014; 345: 150–2.
11. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142: 1264–73.e1.
12. Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene. 2006; 25: 3778–86.
13. Leverero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene. 2006; 25: 3834–47.
14. Yang JD, Kim WR, Coelho R, Mettler TA, Benson JT, Sanderson SO, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011; 9: 64–70.
15. Cederbaum AI, Lu YK, Wu DF. Role of oxidative stress in alcohol-induced liver injury. Arch. Toxicol. 2009; 83: 519–48.
16. Persson EC, Schwartz LM, Park Y, Trabert B, Hollebeck AR, Graubard BI, et al. Alcohol consumption, folate intake, hepatocellular carcinoma, and liver disease mortality. Cancer Epidemiol Biomarkers Prev. 2013; 22: 415–21.
17. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin. Gastroenterol. Hepatol. 2006; 4: 369–80.
18. Park EJ, Lee JH, Yu GY, He GB, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and tnf expression. Cell. 2010; 140: 197–208.
19. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene. 2003; 22: 5093–107.
20. Ghosh S, May MJ, Kopp EB. NF-xb and rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998; 16: 225–60.
21. Escárcega RO, Fuentes-Alexandro S, García-Carrasco M, Gatica A, Zamora A. The transcription factor nuclear factor-kappa B and cancer. Clin Oncol. 2007; 19: 154–61.

22. Deveraux QL, Roy N, Stennicke HR, VanArsdale T, Zhou Q, Srinivasula SM, et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998; 17: 2215–23.

23. Lee JU, Hosotani R, Wada M, DuIR, Kosiba T, Fujimoto K, et al. Role of Bcl-2 family proteins (Bax, Bcl-2 and Bcl-X) on cellular susceptibility to radiation in pancreatic cancer cells. Eur J Cancer. 1999; 35: 1374–80.

24. Vasudevan KM, Gurumurthy S, Rangnekar VM. Suppression of PTEN expression by NF-kB prevents apoptosis. Mol Cell Biol. 2004; 24: 1007–21.

25. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr. NF-kB cells control growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 1999; 19: 5785–99.

26. La Rosa FA, Pierce JW, Sonenshein GE. Differential regulation of the c-myc oncogene promoter by the NF-kappa B rel family of transcription factors. Mol Cell Biol. 1994; 14: 1039–44.

27. Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch. 2005; 456: 475–82.

28. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-kB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004; 431: 461–6.

29. Akira S, Nishio Y, Inoue M, Wang XJ, We S, Matsusaka T, et al. NF-kappaB functions as a tumour promoter in inflammation and cancer. Nature. 2004; 431: 461–6.

30. Giordano V, De Falco G, Chiari R, Quinto I, Pelicci PG, Bartholomew L, et al. Shc mediates IL-6 signaling by interacting with gp130 and Jak2 kinase. J Immunol. 1997; 158: 4097–103.

31. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr. NF-kB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 1999; 19: 5785–99.

32. La Rosa FA, Pierce JW, Sonenshein GE. Differential regulation of the c-myc oncogene promoter by the NF-kappa B rel family of transcription factors. Mol Cell Biol. 1994; 14: 1039–44.

33. Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch. 2005; 456: 475–82.

34. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-kB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004; 431: 461–6.

35. Akira S, Nishio Y, Inoue M, Wang XJ, We S, Matsusaka T, et al. NF-kappaB functions as a tumour promoter in inflammation and cancer. Nature. 2004; 431: 461–6.

36. Ivanov VN, Bhoomik A, Krasilnikov MA, Raz R, Owen-Schaub LB, Levy DE, et al. Cooperation between STAT3 and c-Jun suppresses Fas transcription. Mol Cell. 2001; 7: 517–28.

37. Masuda M, Suzuki M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res. 2002; 62: 3351–5.

38. Kiuchi N, Nakajima K, Ichiba M, Fukuda T, Narimatsu M, Mizuno K, et al. STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med. 1999; 189: 63–73.

39. Aggarwal BB, Kunnunakkara AB, Harikumar KB, Gupta SR, Aggarwal BB, Kunnunakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, et al. Signal transducer and activator of transcription-3, inflammation, and cancer. Ann N Y Acad Sci. 2009; 1171: 59–76.

40. Li WC, Ye SL, Sun RX, Liu YK, Yang ZY, Kim Y, et al. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Clin Cancer Res. 2006; 12: 7140–8.

41. Davis BN, Hata A. Regulation of microRNA biogenesis: a miriad of mechanisms. Cell Commun Signal. 2009; 7: 18.

42. Foulkes WD, Priest JR, Duchaine TF. Dicer1: mutations, microRNAs and mechanisms. Nat Rev Cancer. 2014; 14: 662–72.

43. Stappert J, Roeoe-Koerner B, Brütsch O. The role of microRNAs in human neural stem cells, neuronal differentiation and subtype specification. Cell Tissue Res. 2015; 359: 47–64.

44. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75: 843–54.

45. Negrini M, Ferracin M, Sabbioni S, Croce CM. MicroRNAs in human cancer: from research to therapy. J Cell Sci. 2007; 120: 1833–40.

46. Murakami Y, Yasuda T, Saiko K, Urashima T, Toyoda H, Okanoue T, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumor tissues. Oncogene. 2006; 25: 2537–45.

47. Li W, Xie L, He X, Li J, Tu K, Wu J, et al. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. J Hepatol. 2010; 53: 57–66.

48. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. Ras is regulated by the let-7 microRNA family. Cell. 2005; 120: 635–47.

49. Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between microRNA family. Cell. 2005; 120: 635–47.

50. Wang Y, Lu YW, Toh ST, Sung WK, Tan P, Chow P, et al. Lethal-let-7g inhibits proliferation of hepatocellular carcinoma cells by downregulation of c-Myc and upregulation of p16ink4a. Int J Clin.
Hepatitis B virus X protein inhibits tumor suppressor miR-205 through inducing hypermethylation of miR-205 promoter to enhance carcinogenesis. Neoplasia. 2013; 15: 1282–91.

Cui M, Wang Y, Sun BD, Xiao ZL, Ye LH, Zhang XD. MiR-205 modulates abnormal lipid metabolism of hepatoma cells via targeting acyl-CoA synthetase long-chain family member 1 (ACSL1) mRNA. Biochem Biophys Res Commun. 2014; 444: 270–5.

Liu FY, Zhou SJ, Deng YL, Zhang ZY, Zhang EL, Wu ZR, et al. MiR-216b is involved in pathogenesis and progression of hepatocellular carcinoma through HBx-miR-216b-IGF2BP2 signaling pathway. Cell Death Dis. 2015; 6: e1670.

Yu G, Chen X, Chen S, Ye W, Hou K, Liang M. MiR-19a, miR-122 and miR-223 are differently regulated by hepatitis B virus X protein and involve in cell proliferation in hepatoma cells. J Transl Med. 2016; 14: 122.

Wang CM, Wang Y, Fan CG, Xu FF, Sun WS, Liu YG, et al. miR-29c targets TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. Biochem Biophys Res Commun. 2011; 411: 586–92.

Liu P, Zhang H, Liang X, Ma H, Luan F, Wang B, et al. HBV preS2 promotes the expression of TAZ via miRNA-338-3p to enhance the tumorigenesis of hepatocellular carcinoma. Oncotarget. 2015; 6: 29048–59.

Xu H, Zhao L, Fang Q, Sun J, Zhang S, Zhan C, et al. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α. PLoS One. 2014; 9: e115565.

Wang G, Sun Y, He Y, Ji C, Hu B. MicroRNA-338-3p inhibits cell proliferation in hepatocellular carcinoma by target forkhead box P4 (FOXP4). Int J Clin Exp Pathol. 2015; 8: 337–44.

Fu XY, Tan DM, Hou ZH, Hu ZL, Liu GZ. miR-338-3p is down-regulated by hepatitis B virus X and inhibits cell proliferation by targeting the 3′-UTR region of cyclinD1. Int J Mol Sci. 2012; 13: 8514–39.

Gao HJ, Liu C. miR-429 represses cell proliferation and induces apoptosis in HBV-related HCC. Biomed Pharmacother. 2014; 68: 943–9.

You X, Liu F, Zhang T, Li Y, Ye L, Zhang X. Hepatitis B virus X protein upregulates oncogene Rab18 to result in the dysregulation of lipogenesis and proliferation of hepatoma cells. Carcinogenesis. 2013; 34: 1644–52.

Chen WS, Yen CJ, Chen YJ, Chen JW, Wang LY, Chiu SJ, et al. miRNA-7/21/107 contribute to HBx-induced hepatocellular carcinoma progression through suppression of maspin. Oncotarget. 2015; 6: 25962–74.

Xia W, Ni J, Zhuang J, Qian L, Wang P, Wang J. MiR-103 regulates hepatocellular carcinoma growth by targeting AKAP12. Int J Biochem Cell Biol. 2016; 71: 1–11.

Yen CS, Su ZR, Lee YP, Liu IT, Yen CJ. miR-106b promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 2016; 22: 5183–92.

Shen G, Jia HY, Tai Q, Li YH, Chen DJ. miR-106b downregulates...
adenomatous polyposis coli and promotes cell proliferation in human hepatocellular carcinoma. Carcinogenesis. 2013; 34: 211–9.

80. Mosca N, Castiello F, Coppola N, Trotta MC, Sagnelli C, Pisaturo M, et al. Functional interplay between hepatitis B virus X protein and human miR-125a in HBV infection. Biochem Biophys Res Commun. 2014; 449: 141–5.

81. Bi Q, Tang S, Xia L, Du R, Fan R, Gao L, et al. Ectopic expression of miR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. PLoS One. 2012; 7: e0169.

82. Li JF, Dai XP, Zhang W, Sun SH, Zeng Y, Zhao GY, et al. Upregulation of microRNA-146a by hepatitis B virus X protein contributes to hepatitis development by downregulating complement factor H. mBio. 2015; 6: e02459–14.

83. Zhang Z, Zhang Y, Sun XX, Ma X, Chen ZN. microRNA-146a inhibits cancer metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma. Mol Cancer. 2015; 14: 5.

84. Zou CC, Chen J, Chen K, Wang S, Cao YY, Zhang JN, et al. Functional analysis of miR-181a and its involvement in hepatitis B virus-related hepatocellular carcinoma pathogenesis. Exp Cell Res. 2015; 331: 56–61.

85. Korhan P, Erdal E, Atabey N. miR-181a-5p is downregulated in hepatocellular carcinoma and suppresses motility, invasion and branching-morphogenesis by directly targeting c-Met. Biochem Biophys Res Commun. 2014; 450: 1304–12.

86. Zou CC, Li YG, Cao YY, Zhang JN, Jiang JR, Sheng YR, et al. Upregulated microRNA-181a induces carcinogenesis in hepatitis B virus-related hepatocellular carcinoma by targeting E2F5. BMC Cancer. 2014; 14: 97.

87. Liu X, Zhang Y, Wang P, Wang H, Su H, Zhou X, et al. HBX protein-induced downregulation of microRNA-18a is responsible for upregulation of connective tissue growth factor in HBV infection-associated hepatocarcinoma. Med Sci Monit. 2016; 22: 2492–500.

88. Kong G, Zhang J, Zhang S, Shan C, Ye L, Zhang X. Upregulated microRNA-29a by hepatitis B virus X protein enhances hepatoma cell migration by targeting PTEN in cell culture model. PLoS One. 2011; 6: e19518.

89. Cao YY, Zhang JN, Xiong DM, Wang D, Wu T, Huang AL, et al. Hsa-miR-331-3p inhibits VHL expression by directly targeting its mRNA 3'-UTR in HCC cell lines. Acta Biochim. Pol. 2015; 62: 77–82.

90. Cao Y, Chen J, Wang D, Peng H, Tan X, Xiong D, et al. Upregulated in hepatitis B virus-associated hepatocellular carcinoma cells, miR-331-3p promotes proliferation of hepatocellular carcinoma cells by targeting INGS5. Oncotarget. 2015; 6: 38093–106.

91. Han SY, Han HB, Tian XY, Sun H, Xue D, Zhao C, et al. MicroRNA-33a-3p suppresses cell migration and invasion by directly targeting PBX3 in human hepatocellular carcinoma. Oncotarget. 2016; 7: 42461–73.

92. Guo XF, Wang AY, Liu J. HIFs-miR-33a-Twist1 axis can regulate invasiveness of hepatocellular cancer cells. Eur Rev Med Pharmacol Sci. 2016; 20: 3011–6.

93. Yang L, Ma Z, Wang D, Zhao W, Chen L, Wang G. MicroRNA-602 regulating tumor suppressive gene RASSF1A is over-expressed in hepatitis B virus-infected liver and hepatocellular carcinoma. Cancer Biol Ther. 2010; 9: 803–8.

94. Shyu YC, Lee TL, Lu MJ, Chen JR, Chien RN, Chen HY, et al. miR-122-mediated translational repression of PEG10 and its suppression in human hepatocellular carcinoma. J Transl Med. 2016; 14: 200.

95. Shimakami T, Yamane D, Jangra RK, Kempf BJ, Spaniel C, Barton DJ, et al. Stabilization of hepatitis C virus RNA by an Ago2–mir-122 complex. Proc Natl Acad Sci U S A. 2012; 109: 941–6.

96. Huang JF, Wang Y, Guo YJ, Sun SH. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus–related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology. 2010; 52: 60–70.

97. Huang S, Xie Y, Yang P, Chen P, Zhang L. HCV core protein-induced down-regulation of microRNA-152 promotes aberrant proliferation by regulating wnt1 in HepG2 cells. PLoS One. 2014; 9: e81730.

98. Chen JJ, Tang YS, Huang SF, Ai JG, Wang HX, Zhang LP. HBx protein-induced upregulation of microRNA-221 promotes aberrant proliferation in HBV-related hepatocellular carcinoma by targeting estrogen receptor-α. Oncol Rep. 2015; 33: 792–8.

99. Ding CL, Xu G, Ren H, Zhao LJ, Zhao P, Qi ZT, et al. HCV infection induces the upregulation of miR-221 in NF-κB dependent manner. Virus Res. 2015; 196: 135–9.

100. Mukherjee A, Shrivastava S, Chowdhury JY, Ray R, Ray RB. Transcriptional suppression of miR-181c by hepatitis C virus enhances homeobox A1 expression. J Virol. 2014; 88: 7929–40.

101. Liu DJ, Wu JL, Liu MZ, Yin H, He JT, Zhang B. Downregulation of microRNA-30c and miR-203a is associated with hepatitis C virus core protein-induced epithelial–mesenchymal transition in normal hepatocytes and hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2015; 464: 1215–21.

102. Wan D, Shen S, Fu S, Preston B, Brandon C, He S, et al. miR-203 suppresses the proliferation and metastasis of hepatocellular carcinoma by targeting oncogene ADAM9 and oncogenic long non-coding RNA HULC. Anticancer Agents Med Chem. 2015; 16: 414–23.

103. Kong LL, Ni QF, Lu YT, Ding WZ, Kong LB. miR-30c attenuates invasion and metastasis of hepatocellular carcinoma. Acta Univ Med NanjingNat Sci. 2014; 34: 937–43.

104. Zhang YL, Wei W, Cheng N, Wang KH, Li B, Jiang XQ, et al. Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology. 2012; 56: 1631–40.

105. Xu H, Li G, Yue Z, Li C. HCV core protein-induced upregulation of microRNA-196a contributes to hepatitis development by downregulating complement factor H. mBio. 2015; 6: e02459–14.

106. Singaravelu R, Chen R, Lyn RK, Jones DM, O’Hara S, Rouleau Y,
et al. Hepatitis C virus induced up-regulation of microRNA-27: A novel mechanism for hepatic steatosis. Hepatology. 2014; 59: 98–108.

107. Sun X, Zhang J, Hou Z, Han Q, Zhang C, Tian Z. miR-146a is directly regulated by stat3 in human hepatocellular carcinoma cells and involved in anti-tumor immune suppression. Cell Cycle. 2015; 14: 243–52.

108. Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature. 2000; 408: 86–9.

109. Kloosterman WP, Plasterk RHA. The diverse functions of microRNAs in animal development and disease. Dev cell. 2006; 11: 441–50.

110. Wang Y, Lee CGL. MicroRNA and cancer--focus on apoptosis. J Cell Mol Med. 2009; 13: 12–23.

111. Takata A, Otsuka M, Ohno M, Kishikawa T, Yoshikawa T, Koike K. Mutual antagonism between hepatitis b viral mRNA and host microRNA let-7. Sci Rep. 2016; 6: 23237.

112. Peng Y, Laser J, Shi G, Mittal K, Melamed J, Lee P, et al. Antiproliferative effects by let-7 repression of high-mobility group A2 in uterine leiomyoma. Mol Cancer Res. 2008; 6: 663–73.

113. Wu L, Wang Q, Yao J, Jiang H, Xiao C, Wu F. MicroRNA let-7g and let-7i inhibit hepatoma cell growth concurrently via downregulation of the anti-apoptotic protein B-cell lymphoma-extra large. Oncol Lett. 2015; 9: 213–8.

114. Zhu XM, Wu LJ, Xu J, Yang RW, Wu FS. Let-7c microRNA expression and clinical significance in hepatocellular carcinoma. J Int Med Res. 2011; 39: 2323–9.

115. Jopling C. Liver-specific microRNA-122: Biogenesis and function. RNA Biol. 2012; 9: 137–42.

116. Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA, et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol. 2004; 1: 106–13.

117. Li C, Deng M, Hu J, Li X, Chen L, Ju Y, et al. Chronic inflammation contributes to the development of hepatocellular carcinoma by decreasing miR-122 levels. Oncotarget. 2016; 7: 17021–34.

118. Song K, Han C, Zhang JQ, Lu DD, Dash S, Feitelson M, et al. Epigenetic regulation of microRNA-122 by peroxisome proliferator activated receptor-gamma and hepatitis B virus X protein in hepatocellular carcinoma cells. Hepatology. 2013; 58: 1681–92.

119. Choi Y-H, Kim H-I, Seong JK, Yu D-Y, Cho H, Lee M-O, et al. Hepatitis B virus X protein modulates peroxisome proliferator-activated receptor γ through protein–protein interaction. FEBS Lett. 2004; 557: 73–80.

120. Li CF, Wang YZ, Wang SF, Wu B, Hao JL, Fan HX, et al. Hepatitis B virus mRNA-mediated miR-122 inhibition upregulates PTTG1-binding protein, which promotes hepatocellular carcinoma tumor growth and cell invasion. J Virol. 2013; 87: 2193–205.

121. Coulooarn C, Factor VM, Andersen JB, Durkin ME, Thorgerisson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 2009; 28: 3526–36.

122. Bai S, Nasser MW, Wang B, Hsu SH, Datta J, Kutay H, et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem. 2009; 284: 32015–27.

123. FoRNari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S, et al. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2009; 69: 5761–7.

124. Nakamura M, Kanda T, Sasaki R, Haga Y, Jiang X, Wu S, et al. MicroRNA-122 inhibits the production of inflammatory cytokines by targeting the PKR activator PACT in human hepatic stellate cells. PLoS One. 2015; 10: e0144295.

125. Zhang ZZ, Liu X, Wang DQ, Teng MK, Niu LW, Huang AL, et al. Hepatitis B virus and hepatocellular carcinoma at the microRNA level. World J Gastroenterol. 2011; 17: 3353–8.

126. Sheng YR, Li JB, Zou CC, Wang S, Cao YY, Zhang JN, et al. Downregulation of miR-101-3p by hepatitis b virus promotes proliferation and migration of hepatocellular carcinoma cells by targeting Rab5a. Arch Virol. 2014; 159: 2397–410.

127. Zhang YQ, Guo XD, Xiong L, Kong XY, Xu Y, Liu CF, et al. MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma. FEBS Lett. 2012; 586: 4362–70.

128. Zhuang C, Jiang W, Huang D, Xu L, Yang Q, Zheng L, et al. Serum miR-21, miR-26a and miR-101 as potential biomarkers of hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2016; 40: 386–96.

129. Xu Y, An Y, Wang Y, Zhang C, Zhang H, Huang C, et al. miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells. Oncol Rep. 2013; 29: 2019–24.

130. Zhao S, Zhang Y, Zheng X, Tu X, Li H, Chen J, et al. Loss of microRNA-101 promotes epithelial to mesenchymal transition in hepatocytes. J Cell Physiol. 2015; 230: 2706–17.

131. Sidorkiewicz M, Gerek M, Jozwiak B, Majda-Stanislawska E, Piekaruka A, Bartkowiak J. Expression of microRNA-155 precursor in peripheral blood mononuclear cells from hepatitis C patients after antiviral treatment. Acta Virol. 2010; 54: 75–8.

132. Wang B, Majumder S, Nuovo G, Kutay H, Volinia S, Patel T, et al. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid–defined diet in patients after antiviral treatment. Acta Virol. 2010; 54: 75–8.

133. Chang S, Wang RH, Akagi K, Kim KA, Martin BK, Cavallone L, et al. Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat Med. 2011; 17: 1275–82.

134. O’Connell RM, Kahn DA, Gibson WJ, Round JL, Scholz RL, Chaudhuri AA, et al. MicroRNA-155 promotes autophagy inactivation by enhancing inflammatory T cell development. Immunity. 2010; 33: 607–19.
levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab Invest. 2010; 90: 1727–36.

136. Du T, Zamaro PD. microPrimer: The biogenesis and function of microRNA. Development. 2005; 132: 4645–52

137. Degueurce G, D’Errico I, Pich C, Ibberson M, Schutz F, Montagner A, et al. Identification of a novel PPARδ/Î³/miR-21-3p axis in UV-induced skin inflammation. EMBO Mol Med. 2016; 8: 919–36.

138. Lu TX, Munitz A, Rothenberg ME. MicroRNA-21 is up-regulated in allergic airway inflammation and regulates IL-12p35 expression. J Immunol. 2009; 182: 4994–5002.

139. Zhang ZY, Li ZJ, Gao CP, Chen P, Chen JY, Liu WZ, et al. miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest. 2008; 88: 1358–66.

140. Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature. 2010; 467: 86–90.

141. Peacock O, Lee AC, Cameron F, Tarbox R, Vafadar-Isfahani N, Tufarelli C, et al. Inflammation and miR-21 pathways functionally interact to downregulate PDCD4 in colorectal cancer. PLoS One. 2014; 9: e110267.

142. Xu J, Wu C, Che X, Wang L, Yu DK, Zhang TW, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog. 2011; 50: 136–42.

143. Meng FY, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007; 133: 647–58.

144. Qiu X, Dong S, Qiao F, Lu S, Song Y, Lao Y, et al. HBx-mediated miR-21 upregulation represses tumor-suppressor function of PDCD4 in hepatocellular carcinoma. Oncogene. 2013; 32: 3296–305.

145. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65: 7065–70.

146. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005; 65: 6029–33.

147. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafrè SA, et al. miR-21 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem. 2007; 282: 23716–24.

148. Rong MH, Chen G, Dang YW. Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro. BMC Cancer. 2013; 13: 21.

149. Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeraas G, Voros D. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog. 2013; 52: 297–303.

150. Ogawa T, Enomoto M, Fujii H, Sekiya Y, Yoshizato K, Ikeda K, et al. MicroRNA-21/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut. 2012; 61: 1600–9.

151. Yuan QG, Loya K, Rani B, Mobus S, Balakrishnan A, Lamle J, et al. MicroRNA-221 overexpression accelerates hepatocyte proliferation during liver regeneration. Hepatology. 2013; 57: 299–310.

152. le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 2007; 26: 3699–708.

153. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p21Waf1. J Biol Chem. 2008; 283: 29897–903.

154. Garofalo M, Quintavalle C, Di Leva G, Zanca C, Romano G, Taccioli C, et al. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene. 2008; 27: 3845–55.

155. Fu XH, Wang Q, Chen JS, Huang XH, Chen XL, Cao LQ, et al. Clinical significance of miR-221 and its inverse correlation with P27Kip1 in hepatocellular carcinoma. Mol Biol Rep. 2010; 38: 3029–35.

156. Garofalo M, Di Leva G, Romano G, Nuovo G, Suba S, Ngeinkeu A, et al. miR-221& 222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell. 2009; 16: 496–509.

157. Bae HJ, Jung KH, Eun JW, Shen QY, Kim HS, Park SJ, et al. MicroRNA-221 governs tumor suppressor HDAC6 to potentiate malignant progression of liver cancer. J Hepatol. 2015; 63: 408–19.

158. Park J, Kogure T, Nuovo GJ, Jiang J, He L, Kim JH, et al. miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res. 2011; 71: 7608–16.

159. Callegari E, Elamin BK, Giannone F, Milazzo M, Altavilla G, FoRNAri F, et al. Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology. 2012; 56: 1025–33.

160. Huan L, Bao C, Chen D, Li Y, Lian J, Ding J, et al. MicroRNA-129-5p targets the biliarverdin reductase B/nuclear factor-xB pathway to suppress cell growth in hepatocellular carcinoma cells. Cancer Sci. 2016; 107: 258–66.

161. Liu Y, Hei Y, Shu Q, Dong J, Gao Y, Fu H, et al. VCP/p97, down-regulated by microRNA-129-5p, could regulate the progression of hepatocellular carcinoma. PLoS One. 2012; 7: e35800.

162. Bao C, Li Y, Huan L, Zhang Y, Zhao F, Wang Q, et al. NF-κB signaling relieves negative regulation by miR-194 in hepatocellular carcinoma by suppressing the transcription factor HNF-1α. Sci Signal. 2015; 8: ra73.

163. Ding J, Huang SL, Wang Y, Tian Q, Zha RP, Shi HB, et al. Genome-wide screening reveals that miR-195 targets the TNF-α/NF-κB pathway by down-regulating IkB kinase alpha and TAB3 in hepatocellular carcinoma. Hepatology. 2013; 58: 654–66.

164. Zhao N, Wang R, Zhou L, Zhu Y, Gong J, Zhuang SM. MicroRNA-26b suppresses the NF-κB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting...
179. Lu YX, Yue XP, Cui YY, Zhang JF, Wang KW. MicroRNA-124 suppresses growth of human hepatocellular carcinoma by targeting STAT3. Biochem Biophys Res Commun. 2013; 441: 873–9.

180. Gong J, Zhang JP, Li B, Zeng C, You K, Chen MX, et al. MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R. Oncogene. 2012; 32: 3071–9.

181. Lin YH, Wu MH, Liao CJ, Huang YH, Chi HC, Wu SM, et al. Repression of microRNA-130b by thyroid hormone enhances cell motility. J Hepatol. 2015; 62: 1328–40.

182. Wang H, Su X, Yang M, Chen T, Hou J, Li N, et al. Reciprocal control of miR-197 and IL-6/STAT3 pathway reveals miR-197 as a potential therapeutic target for hepatocellular carcinoma. Oncoimmunology. 2015; 4: e1031440.

183. Zhou B, Chen H, Wei D, Kuang Y, Zhao X, Li G, et al. A novel miR-219-5p/SR22.G2A/ST3 regulatory pathway in human hepatocellular carcinoma. J Exp Clin Cancer Res. 2014; 33: 55.

184. Yang X, Liang L, Zhang XF, Jia HL, Qin Y, Zhu XC, et al. MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6–Stat3 pathway. Hepatology. 2013; 58: 158–70.

185. Zhou P, Huang G, Zhao YY, Zhong D, Xu ZZ, Zeng YJ, et al. MicroRNA-363 mediated downregulation of S1PR1 enhances proliferation of hepatocellular carcinoma cells. Cell Signal. 2014; 26: 1347–54.

186. Zhang JF, He ML, Fu WM, Wang H, Chen LZ, Zhu X, et al. Primate-specific microRNA-637 inhibits tumorigenesis in hepatocellular carcinoma by disrupting signal transducer and activator of transcription 3 signaling. Hepatology. 2011; 54: 2137–48.

187. Yan XL, Jia YL, Chen L, Zeng Q, Zhou JN, Fu CJ, et al. Hepatocellular carcinoma-associated mesenchymal stem cells promote hepatocarcinogenesis progression: Role of the S100A-4/miR155-SOCS1-MMP9 axis. Hepatology. 2013; 57: 2274–86.

188. Zhou J, Yu L, Gao X, Hu J, Wang JP, Dai Z, et al. Plasma microRNA panel to diagnose hepatitis B virus–related hepatocellular carcinoma. J Clin Oncol. 2011; 29: 4781–8.

189. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009; 361: 1437–47.

190. Chai ZT, Zhu XD, Ao YJ, Wang WQ, Gao DM, Kong J, et al. MicroRNA-26a suppresses recruitment of macrophages by down-regulating macrophage colony-stimulating factor expression through the PI3K/Akt pathway in hepatocellular carcinoma. J Hematol Oncol. 2015; 8: 56.

191. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol. 2008; 26: 2707–16.

192. Huang JY, Zhang K, Chen DQ, Chen J, Feng R, Song HZ, et al. MicroRNA-451: Epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocellular carcinoma. Oncotarget.
Overexpression of miR-370 and downregulation of its novel target TGFβ-RII contribute to the progression of gastric carcinoma. Oncogene. 2012; 31: 226–37.

207. Wu Z, Sun H, Zeng W, He J, Mao X. Upregulation of microRNA-370 induces proliferation in human prostate cancer cells by downregulating the transcription factor FOXO1. PLoS One. 2012; 7: e445825.

208. Dixonmclver A, East P, Mein CA, Cazier JB, Molloy G, Chaplin T, et al. Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PLoS One. 2008; 3: e2141.

209. Zhang XL, Zeng JP, Zhou MR, Li BN, Zhang YY, Huang T, et al. The tumor suppressive role of miRNA-370 by targeting FoxM1 in acute myeloid leukaemia. Mol Cancer. 2012; 11: 56.

210. Chang KW, Chu TH, Gong NR, Chiang WF, Yang CC, Liu CJ, et al. miR-370 modulates insulin receptor substrate-1 expression and inhibits the tumor phenotypes of oral carcinoma. Oral Dis. 2013; 19: 611–9.

211. Sun G, Hou YB, Jia HY, Bi XH, Yu L, Chen D. miR-370 promotes cell death of liver cancer cells by Akt/FoxO3a signalling pathway. Eur Rev Med Pharmacol Sci. 2016; 20: 2011–9.

212. Zhou X, Zhu HQ, Ma CQ, Li HG, Liu FF, Chang H, et al. MiR-1180 promoted the proliferation of hepatocellular carcinoma cells by repressing TNIP2 expression. Biomed Pharmacother. 2016; 79: 315–20.

213. Sun SC. CYLD: A tumor suppressor deubiquitinae regulating NF-κB activation and diverse biological processes. Cell Death Differ. 2010; 17: 25–34.

214. Zhang XY, Liu SR, Hu TS, Liu SP, He Y, Sun SH. Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology. 2009; 50: 490–9.

215. Scisciani C, Vossio S, Guerrieri F, Schinzari V, De Iaco R, De Meo PD, et al. Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways. J Hepatol. 2012; 56: 855–61.

216. Zhang K, Chen J, Chen DQ, Huang JY, Feng B, Han SQ, et al. Aurora-a promotes chemoresistance in hepatocellular carcinoma by targeting NF-κB inflammatory pathways. Oncotarget. 2014; 5: 12916–35.

217. Zhang N, Duan WD, Leng JJ, Zhou L, Wang X, Xu YZ, et al. STAT3 regulates the migration and invasion of a stem-like subpopulation through microRNA-21 and multiple targets in hepatocellular carcinoma. Oncol Rep. 2015; 33: 1493–8.

218. Wang B, Hsu SH, Frankel W, Ghoshal K, Jacob ST. Stat3-mediated activation of miRNA-23a suppresses gluconeogenesis in hepatocellular carcinoma by down-regulating Glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha. Hepatology. 2012; 56: 186–97.

219. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005; 5: 331–42.

220. Agresti A, Lupo R, Bianchi M, Muller S. HMGB1 interacts differentially with members of the Rel family of transcription factors.
factors. Biochem Biophys Res Commun. 2003; 302: 421–46.

221. Chen M, Liu Y, Varley P, Chang Y, He XX, Huang H, et al. High-mobility group box 1 promotes hepatocellular carcinoma progression through miR-21-mediated matrix metalloproteinase activity. Cancer Res. 2015; 75: 1645–56.

222. Zhong W, Qin S, Zhu B, Pu M, Liu F, Wang L, et al. Oxyysterol-binding protein-related protein 8 (ORP8) increases sensitivity of hepatocellular carcinoma cells to Fas-mediated apoptosis. J Biol Chem. 2015; 290: 8876–87.

223. Zhang ZQ, Meng H, Wang N, Liang LN, Liu LN, Lu SM, et al. Serum microRNA 143 and microRNA 215 as potential biomarkers for the diagnosis of chronic hepatitis and hepatocellular carcinoma. Diagn Pathol. 2015; 9: 135.

224. Zhuang LP, Meng ZQ. Serum miR-224 reflects stage of hepatocellular carcinoma and predicts survival. Biomed Res Int. 2015; 2015: 731781.

225. Li Q, Ding CC, Chen C, Zhang ZM, Xiao H, Xie F, et al. miR-224 promotion of cell migration and invasion by targeting homeobox D10 gene in human hepatocellular carcinoma. J Gastroenterol Hepatol. 2014; 29: 835–42.

226. An F, Olaru AV, Mezey E, Xie Q, Li L, Piontek KB, et al. MicroRNA-224 induces G1/S checkpoint release in liver cancer. J Clin Med. 2015; 4: 1713–28.

227. Liu YM, Berthier-Schaad Y, Fallin MD, Fink NE, Tracy RP, Klag MJ, et al. IL-6 haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic dialysis cohort. J Am Soc Nephrol. 2006; 17: 863–70.

228. Huang SL, He XY, Ding J, Liang LH, Zhao YJ, Zhang ZF, et al. Upregulation of miR-23a~27a~24 decreases transforming growth factor-beta-induced tumor-suppressive activities in human hepatocellular carcinoma cells. Int J Cancer. 2008; 123: 972–8.

229. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature. 2005; 438: 685–9.

230. He XD, Li JJ, Guo WD, Liu W, Yu J, Song W, et al. Targeting the microRNA-21/Ap1 axis by 5-fluorouracil and pirarubicin in human hepatocellular carcinoma. Oncotarget. 2014; 6: 2302–14.

231. Yu W, Fang H. Clinical trials with oncolytic adenovirus in china. Curr Cancer Drug Targets. 2007; 7: 141–8.

232. Callegari E, Elamin BK, D’Abundo L, Falzoni S, Donvito G, Moshiri F, et al. Anti-tumor activity of a miR-199-dependent oncolytic adenovirus. PLoS One. 2013; 8: e73964.

233. Ghosh AS, Tergaonkar V. Telomeres and inflammation: Rap1 joins the ends? Cell Cycle. 2010; 9: 3834–5.

234. Zha Y, Gan P, Yao Q, Ran FM, Tan J. Downregulation of Rap1 promotes 5-fluorouracil-induced apoptosis in hepatocellular carcinoma cell line HepG2. Oncol Rep. 2014; 31: 1691–8.

235. Eggert T, McGlynn KA, Duffy A, Manns MP, Greten TF, Altekruse SF. Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000–10. Gut. 2013; 62: 1667–8.

236. Lin XJ, Chong YT, Guo ZW, Xie C, Yang XJ, Zhang Q, et al. A serum microRNA classifier for early detection of hepatocellular carcinoma: A multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol. 2015; 16: 804–15.

Cite this article as: Huan L, Liang L, He X. Role of microRNAs in inflammation-associated liver cancer. Cancer Biol Med. 2016; 13: 407-25. doi: 10.20892/j.isssn.2095-3941.2016.0071